Rapport Therapeutics Financials - Benzinga

Rapport Therapeutics Inc

RAPPNASDAQ

Trade with Public

Trade with Public

$40.45

-1.50-3.58%

At close: Sep 17, 5:00 PM EST

$40.45

-1.50-3.58%

Pre-Market: 4:01 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Rapport Therapeutics Financials

Rapport Therapeutics (RAPP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.96) by 23.96 percent. This is a 58.67 percent decrease over losses of $(0.75) per

Benzinga Newsdesk

PRO
Rapport Therapeutics Q1 EPS $(0.42) Beats $(0.65) Estimate, Sales $20.000M Beat $8.571M Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.65) by 35.38 percent. This is a 38.24 percent increase over losses of $(0.68) per share

Benzinga Newsdesk

PRO
Rapport Therapeutics Q4 EPS $(0.72) Misses $(0.69) Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.69) by 5.11 percent. This is a 26.32 percent decrease over losses of $(0.57) per share

Benzinga Newsdesk

PRO
Rapport Therapeutics Q3 EPS $(0.71) Beats $(0.77) Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.19 percent. This is a 42 percent decrease over losses of $(0.50) per share from

Benzinga Newsdesk

Gold Moves Higher; Robinhood Shares Jump

Avi Kapoor

PRO
Rapport Therapeutics Q2 EPS $(0.75) Beats $(0.85) Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.85) by 11.45 percent. This is a 55.88 percent increase over losses of $(1.70) per share

Benzinga Newsdesk